Insilico Launches Longevity Vaccines Research to Clear Early Drivers of Aging
The program uses generative AI and circular mRNA to design single-dose, self-limiting therapies that direct a patient’s own T cells against the cells that start age-related disease, beginning with the immune system.
Anton Dalsätt · 4 min read
Rentosertib Linked to a Younger Proteomic Age in an IPF Trial
Six proteomic aging clocks, applied to blood samples from a Phase IIa study of Insilico’s AI-designed lung-fibrosis drug, each pointed toward a lower predicted biological age in treated patients.
William Ferreira Andrén · 5 min read
Anthropic Launches "Claude Science," an AI Workbench Aimed at Biology and Drug Discovery
The company behind Claude has released a research environment that pulls genomics, proteomics, and cheminformatics tools into one place — and is offering academic labs up to $30,000 in credits to try it.
Editorial Team · 4 min read
Insilico Medicine Signs AI Drug-Discovery Deal With SK Biopharmaceuticals Worth Up to $2.5 Billion
The AI-driven biotech will run target-to-candidate discovery for neuroimmune disorders, while its Korean partner takes the molecules through late-stage development - Insilico's largest potential deal in Asia-Pacific to date.
Editorial Team · 4 min read